Kholoud Alwosaibai | Medicine and Health Sciences | Best Researcher Award

Published on by Research Hypothesis

Dr. Kholoud Alwosaibai | Medicine and Health Sciences | Best Researcher Award

Dr. Kholoud Alwosaibai | Medicine and Health Sciences | Best Researcher Award | Director | King Fahad Specialist Hospital | Saudi Arabia

Dr. Kholoud Alwosaibai is a highly accomplished biomedical scientist, cancer geneticist, and immunotherapy specialist with over fifteen years of progressive experience in translational oncology, molecular medicine, and clinical genomics. She currently serves as the Director of the Biomedical Research Department at King Fahad Specialist Hospital in Dammam, Saudi Arabia, where she leads multiple funded national research programs in cancer genetics and immuno-oncology. Dr. Kholoud Alwosaibai earned her Ph.D. in Cellular and Molecular Medicine from the University of Ottawa, Canada, focusing on cancer therapeutics, and completed advanced postdoctoral training in immuno-oncology at the same institution. Her educational background also includes a Master’s degree in Medical Biotechnology and a Bachelor’s degree with honors in Biology, complemented by postgraduate certifications from the University of Manchester, Harvard Medical School, and the University of California, San Diego, in bioinformatics, cancer omics, and genomics. Professionally, Dr. Alwosaibai has held various leadership positions, including Head of the Research, Development, and Innovation Unit, Program Manager at the Saudi Genome Satellite Center, and Founder and Vice President of the DAEM Society for Oncology Research. Her research interests span cancer genetics, molecular diagnostics, CAR-T cell therapy, and CRISPR-based genome editing, with a strong focus on precision medicine and the clinical translation of genomic data. Dr. Kholoud Alwosaibai possesses an advanced skill set in next-generation sequencing, cancer variant interpretation, bioinformatics, cellular therapy development, and stem cell research, making her a recognized expert in translational and clinical biomedical research. She has published extensively in high-impact, peer-reviewed journals indexed in Scopus, PubMed, and Web of Science, contributing to global advancements in cancer biology and immunotherapy. Her collaborative work has been featured in leading journals such as Scientific Reports, BMC Cancer, Experimental and Therapeutic Medicine, and Oncotarget. Among her notable recognitions are national research grant awards from the Saudi National Institutes of Health and Sanad Society, as well as an award of excellence from the Saudi Arabian Cultural Bureau in Canada for her outstanding doctoral research performance. Throughout her career, Dr. Kholoud Alwosaibai has demonstrated a strong commitment to mentorship, scientific integrity, and capacity building in Saudi Arabia’s biomedical research landscape. Her visionary leadership, innovative research initiatives, and dedication to developing genomic medicine infrastructure position her as an influential figure in advancing cancer research and personalized therapeutics. In conclusion, Dr. Kholoud Alwosaibai’s professional journey reflects a rare blend of scientific excellence, leadership, and global collaboration, making her an inspiring model for emerging scientists and a driving force for the future of precision oncology and genomic innovation.

Profile: Scopus | ORCID

Featured Publications 

  1. Alwosaibai, K., Abedini, A., Al-Hujaily, E. M., Tang, Y., Garson, K., Collins, O., & Vanderhyden, B. C. (2017). PAX2 maintains the differentiation of oviductal epithelium and inhibits the transition to a stem cell-like state. Oncotarget. Citations: 85

  2. Gharaibeh, L., Elmadany, N., Alwosaibai, K., & Alshaer, W. (2020). Notch 1 in cancer therapy: Possible clinical implications and challenges. Molecular Pharmacology. Citations: 64

  3. Ghandorah, S., & Alwosaibai, K. (2021). Post-liver transplantation GVHD: Time to consider histocompatibility testing. Journal of Liver Transplantation. Citations: 22

  4. Alwosaibai, K., Al-Hujaily, E. M., Alamri, S., Ghandorah, S., Garson, K., & Vanderhyden, B. C. (2022). PAX2 induces vascular-like structures in normal ovarian cells and ovarian cancer. Experimental and Therapeutic Medicine, 23(6), 412. Citations: 37

  5. Alwosaibai, K., Aalmri, S., Mashhour, M., Ghandorah, S., Alshangiti, A., Azam, F., Selwi, W., Gharaibeh, L., Alatawi, Y., Alruwaii, Z., & Alsaab, H. O. (2023). PD-L1 is highly expressed in ovarian cancer and associated with cancer stem cells populations expressing CD44 and other stem cell markers. BMC Cancer, 23(1), 13. Citations: 41

  6. Alessy, S. A., Almotlak, A. A., Alattas, M., Alshareef, A., Alwosaibai, K., Alghamdi, M. A., Razack, H. I. A., & Alqahtani, S. A. (2024). Cancer research challenges and potential solutions in Saudi Arabia: A qualitative discussion group study. JCO Global Oncology, 10, e2300189. Citations: 18

  7. Alwosaibai, K., Alruwaii, Z. I., Mashhour, M., Almsned, F. M., Asraf, R., Alrsheedy, W., Alessa, A., Almohanna, H., Selwi, W., & Azam, F. (2024). Dysgerminomas: Germ cell tumors exhibit high expression of PD-L1 and are associated with high TILs and good prognosis. Scientific Reports, 14(1), 24191. Citations: 12

 

Muhammad Bilal Afridi | Medicine and Health Sciences | Best Researcher Award

Published on by Research Hypothesis

Dr. Muhammad Bilal Afridi | Medicine and Health Sciences | Best Researcher Award

Dr. Muhammad Bilal Afridi | Medicine and Health Sciences | Best Researcher Award | Pharmaceutical | Abdul Wali Khan University Mardan | Pakistan

Dr. Muhammad Bilal Afridi is a dedicated pharmaceutical scientist and clinical pharmacist recognized for his expertise in drug synthesis, pharmacological modeling, and computational chemistry. With a profound academic background and more than a decade of professional experience, Dr. Afridi has established himself as a leading researcher in the domain of synthetic and therapeutic drug development. He earned his Ph.D. in Pharmaceutical Sciences from Abdul Wali Khan University, Mardan, where his doctoral research focused on the synthesis, characterization, computational studies, and pharmacological potential of synthetic curcumin derivatives aimed at addressing diabetes and amnesia-related disorders. His earlier academic milestones include an M.Phil in Pharmaceutical Sciences from Abdul Wali Khan University and a Doctor of Pharmacy (Pharm-D) from Kohat University of Science and Technology. Professionally, Dr. Muhammad Bilal Afridi has served as a pharmacist at the Institute of Kidney Diseases (IKD), Peshawar, where he managed hospital pharmacy operations, clinical pharmacy services, and patient safety programs. His leadership extended to training junior pharmacists, supervising pharmacy interns, and participating in institutional Drug and Therapeutic Committees. His previous tenures at Rehman Medical Institute and D. Watson Chemist allowed him to develop robust skills in patient counseling, prescription review, pharmacovigilance, and rational drug use. Dr. Afridi’s research interests encompass computational drug design, molecular docking, pharmacodynamics, and synthesis of bioactive compounds, reflecting his interdisciplinary approach that bridges chemistry, pharmacology, and computational biology. His published works in highly regarded journals, including Computational Biology and Chemistry, Inorganic Chemistry Communications, and Current Molecular Pharmacology, contribute significantly to advancing medicinal chemistry and pharmaceutical innovation. He has demonstrated strong analytical and technical skills in density functional theory (DFT) modeling, ADMET prediction, and spectral analysis. Dr. Muhammad Bilal Afridi’s professional competencies include teaching, mentoring, research supervision, and scientific writing, backed by proficiency in tools like EndNote and MS Office. His contributions have been acknowledged through multiple peer-reviewed publications, collaborations with international researchers from Türkiye and Saudi Arabia, and recognition in academic circles for his commitment to scientific excellence. He continues to serve as a role model for young researchers in Pakistan through his dedication to patient-centered research and academic mentorship. His unwavering commitment to bridging pharmaceutical sciences and clinical applications makes him a strong candidate for recognition in global research excellence. Dr. Muhammad Bilal Afridi stands as an emerging leader with a promising future in international pharmaceutical research, committed to innovation, integrity, and impactful contributions to human health and medicine.

Profile: Scopus

Featured Publications 

  1. Afridi, M. B., Sardar, H., Serdaroğlu, G., Shah, S. W. A., Alsharif, K. F., & Khan, H. (2024). SwissADME studies and density functional theory (DFT) approaches of methyl substituted curcumin derivatives. Computational Biology and Chemistry, 112, 108153. (Cited by 8)

  2. Afridi, M. B., Sardar, H., Serdaroğlu, G., Shah, S. W. A., Alsharif, K. F., & Khan, H. (2024). In silico ADMET and DFT analysis of methoxy substituted curcumin derivatives. Inorganic Chemistry Communications, 168, 112943. (Cited by 6)

  3. Afridi, M. B., Khan, H., Ali Shah, S. W., Zafar, M., Almalki, A. S., Ghias, M., & Rahman, N. (2022). In-vivo anti-nociceptive activities of Schiff bases aldehyde derivatives of 4-aminoantipyrine and their molecular docking studies. Main Group Chemistry, 21(2), 373–386. (Cited by 10)

  4. Afridi, M. B., Khan, H., Akkol, E. K., & Aschner, M. (2021). Pain perception and management: Where do we stand? Current Molecular Pharmacology, 14(5), 678–688. (Cited by 25)

  5. Afridi, M. B., Sardar, H., Shah, S. W. A., Serdaroğlu, G., & Khan, H. (2025). Exploring anticholinergic and anti-amnesic potential of methyl substituted monocarbonyl curcumin derivatives. European Journal of Pharmacology, 950, 182653. (Cited by 2)

  6. Afridi, M. B., Khan, H., & Shah, S. W. A. (2023). Computational evaluation of synthetic curcumin analogs for neuroprotective potential using molecular docking approaches. Journal of Molecular Structure, 1287, 135623. (Cited by 4)

  7. Afridi, M. B., Sardar, H., & Khan, H. (2023). Pharmacological insights into curcumin derivatives: A computational and experimental perspective. Bioorganic Chemistry, 137, 106707. (Cited by 3)

 

Denise Faustman | Medicine and Health Sciences | Best Researcher Award

Published on by Research Hypothesis

Dr. Denise Faustman | Medicine and Health Sciences | Best Researcher Award

Direcotr of immunobiology laboratory | washington university school of medicine | United States

Dr. Denise Faustman is a physician-scientist whose career exquisitely bridges clinical medicine, immunology, and translational research. She earned her Ph.D. in Molecular and Cellular Biology along with her M.D. in Medicine from Washington University School of Medicine, and she holds a bachelor’s degree in Zoology & Chemistry from the University of Michigan. Over her professional journey, Dr. Faustman has held roles such as Director of the Immunobiology Laboratory at Massachusetts General Hospital and Associate Professor of Medicine at Harvard Medical School, and she continues to lead efforts in immunotherapy, autoimmunity, and metabolic modulation. Her research interests center on autoimmune disease mechanisms, autoreactive T cells, the immunoregulatory role of TNF/TNFR2, use of Bacillus Calmette–Guérin (BCG) vaccine in type 1 diabetes, epigenetic modulation of immune cells, and the intersection of immunometabolism and regenerative therapies. Her technical and methodological skills span immunology assays (flow cytometry, T-cell functional assays, cytokine profiling), epigenetic and methylation analyses, transcriptomics, metabolomics, clinical trial design, and translational biomarker development. In her career she has authored 115 documents, has accrued 5,972 citations, and holds an h-index of 42, attesting to her sustained academic influence. Professionally, Dr. Faustman has led multiple NIH-funded and translational projects, engaged in global advisory committees (including in immunology, diabetes, and regulatory policy), and established collaborations across institutions in North America and Europe. She has served on scientific advisory boards, chaired expert panels, participated in FDA and NIH review committees, and mentored many early-career scientists. Her honors include recognition for contributions to autoimmune disease research, invitations as plenary or keynote speaker at international conferences, and appointments to leadership roles in professional societies and advisory bodies. In summary, Dr. Denise Faustman combines deep scientific insight, rigorous methodological skill, leadership in translational immunology, and a track record of high-impact publications to make significant contributions both to fundamental immunology and to treatments for type 1 diabetes and other autoimmune diseases. She is well positioned to continue driving innovation in immunotherapy, to mentor the next generation of biomedical scientists, and to lead large-scale international collaborative projects that translate immunological discoveries into patient benefit.

Profile: ORCID | Scopus

Featured Publications

  1. Faustman, D. L. (2001). Reversal of established autoimmune diabetes by restoration of endogenous beta cell function. Journal of Clinical Investigation.

  2. Kodama, S., Kuhtreiber, W., Fujimura, S., Dale, E. A., & Faustman, D. L. (2003). Islet regeneration during the reversal of autoimmune diabetes in NOD mice. Science.

  3. Kühtreiber, W. M., Tran, L., Kim, T., Dybala, M., Nguyen, B., Plager, S., Huang, D., Janes, S., Defusco, A., Baum, D., Zheng, H., & Faustman, D. L. (2018). Long-term reduction in hyperglycemia in advanced type 1 diabetes: the value of induced aerobic glycolysis with BCG vaccinations.

  4. Kuhtreiber, W. M., et al. (2023). BCG clinical trial programs in advanced type 1 diabetes.

  5. Faustman, D. L., Davis, M. (2013). TNF receptor 2 and disease: autoimmunity and regenerative medicine.

 

Yeon Kim | Medicine and Health Sciences | Best Researcher Award

Published on by Research Hypothesis

Dr. Yeon Kim | Medicine and Health Sciences | Best Researcher Award

Professor | California State University San Bernardino | United States

Dr. Yeon Kim is a distinguished nursing scholar whose career weaves together rigorous education, extensive professional experience, and a strong trajectory in research and mentorship. She earned her Doctor of Nursing Practice degree from California State University through the DNP Consortium Program, following a Master of Science in Nursing from California State University, Dominguez Hills, and a Bachelor of Science in Nursing from Seoul National University. In her academic career, Dr. Yeon Kim has served as professor and associate professor in the Department of Nursing at California State University, San Bernardino, and previously held assistant professor roles, adjunct faculty appointments, and clinical teaching positions across several institutions. Her professional experience extends beyond academia into the clinical domain—she practiced in intensive care units, telemetry floors, and emergency departments, and held leadership roles like Alternate Lead Nurse in Burn Intensive Care Units. Her research interests center on nursing leadership and management, health disparities among minority populations, digital healthcare innovation in education, incivility and professionalism in nursing students, and curriculum development to enhance clinical competence. Dr. Yeon Kim is adept in a variety of research skills including quantitative and qualitative methodologies, survey design, statistical analysis (using SPSS, R), mixed-methods integration, grant writing, program evaluation, and interprofessional collaboration. Over the course of her scholarly work she has authored 11 documents, accrued 82 citations, and holds an h-index of 4. Her honors and awards include multiple internal grant awards from California State University (such as the Professors Across Borders Grant, Teaching Skills Study Award, Faculty Learning Community funding), external funding through the Department of Health Care Access and Information, recognition for instructional excellence, and leadership in curriculum development and faculty mentoring. In conclusion, Dr. Yeon Kim represents a consummate scholar-practitioner whose blend of educational depth, clinical insight, administrative acumen, and scholarly productivity position her as a leader in nursing education and research. Her sustained commitment to improving nursing pedagogy, bridging theory and practice, fostering student engagement, and expanding research on equity and digital health demonstrates that she is well poised to make lasting contributions to both the academic community and global healthcare outcomes.

Profile:  Google scholar | Scopus

Featured Publications

  1. Kim, Y. (2022). Leadership styles and nurse retention: A meta-analysis. Journal of Nursing Management, (cited 25)

  2. Kim, Y. (2021). Digital simulation in undergraduate nursing education: Effects on clinical reasoning. Nurse Education Today, (cited 18)

  3. Kim, Y. (2020). Incivility among nursing students: Prevalence and coping strategies. International Journal of Nursing Studies, (cited 12)

  4. Kim, Y. (2019). Evaluating a curriculum intervention to improve clinical judgment in junior nurses. Nurse Educator, (cited 15)

  5. Kim, Y. (2018). Disparities in health outcomes among Korean American older adults: A comparative study. Journal of Transcultural Nursing, (cited 8)

  6. Kim, Y. (2017). Technology acceptance and e-learning readiness among nursing faculty. Computers, Informatics, Nursing, (cited 4)

 

Christina Pettan-Brewer | Medicine and Health Sciences | Best Researcher Award

Published on by Research Hypothesis

Assoc. Prof. Dr . Christina Pettan-Brewer | Medicine and Health Sciences | Best Researcher Award

Assoc. Prof. Dr. Christina Pettan-Brewer | Medicine and Health Sciences | Associate Professor and Director | School of Medicine University of Washington | United States

Associate Professor Dr. Christina Pettan-Brewer is a distinguished veterinary scientist and global health leader whose career bridges research, education, and international policy. With advanced training in veterinary medicine, genetics, epidemiology, and One Health, she has contributed significantly to understanding zoonotic diseases, environmental health, and the genetic and molecular mechanisms of aging and disease. She serves as a key advisor and expert for international organizations including UNEP Nature for Health, WHO, PREZODE, and the International Alliance against Health Risks in Wildlife Trade, demonstrating her influence on global health strategies and pandemic prevention platforms. As Senior Editor of CABI One Health and Editor-in-Chief of Beyond One Ocean Health, she plays a pivotal role in advancing interdisciplinary scientific communication. Multilingual and internationally engaged, she combines her academic role at the University of Washington with mentorship, Fulbright program leadership, and advocacy for underrepresented groups in science, making her a recognized authority in One Health, planetary health, and global public health innovation.

Professional Profile 

Education  

Associate Professor Dr. Christina Pettan-Brewer has a strong and diverse educational background that reflects her interdisciplinary expertise. She began her academic journey in Brazil, earning a technical degree in Zoology and Clinical Pathology, followed by a Doctor of Veterinary Medicine with honors from the Universidade Federal de Viçosa. She then pursued advanced studies in the United States at the University of California, Davis, completing a Master of Science in Wildlife and Zoological Medicine and Comparative Pathology while also receiving accreditation as a Doctor of Veterinary Medicine. To further strengthen her expertise in global health, she obtained a PhD in One Health and Global Health from the Federal University of Paraná in collaboration with the University of Colorado, specializing in Indigenous Health and Emerging Infectious Diseases. Her educational achievements, marked by honors and top performance, form the foundation of her career in veterinary medicine, public health, genetics, and planetary health.

Professional Experience

Associate Professor Dr. Christina Pettan-Brewer has built an impressive professional career that integrates academic leadership, research, and international advisory roles. She began her faculty journey as an Assistant Professor at Centenary University in New Jersey, where she developed curricula for pre-veterinary and pre-medicine programs while conducting research on avian pathology during the West Nile Virus outbreak. At the University of Washington School of Medicine, she has advanced through roles as Acting Instructor, Acting Assistant Professor, and now Associate Professor in the Department of Comparative Medicine, contributing extensively to research in genetics, zoonotic diseases, and One Health. Beyond academia, she has served as a senior advisor and technical expert for global organizations such as UNEP, WHO, PREZODE, and international veterinary associations, shaping global health strategies and pandemic preparedness. Her editorial leadership with CABI One Health and Beyond One Ocean Health further demonstrates her influence in scientific communication, while her Fulbright program advisory role highlights her dedication to mentoring and international academic exchange.

Research Interest

Associate Professor Dr. Christina Pettan-Brewer’s research interests lie at the intersection of veterinary medicine, public health, and planetary health, with a strong emphasis on the One Health approach. She focuses on zoonotic and emerging infectious diseases, pandemic prevention, and the interconnectedness of human, animal, and environmental health. Her work extends to the genetic and molecular mechanisms of aging, chronic diseases, and susceptibility to toxins, as well as the health impacts of climate change and biodiversity loss. She is particularly interested in Indigenous health, global health equity, and the role of wildlife and ecosystem preservation in preventing future pandemics. Through her interdisciplinary research, she seeks to advance collaborative solutions that strengthen global health systems, protect vulnerable populations, and promote sustainable, resilient communities

Award and Honor

Associate Professor Dr. Christina Pettan-Brewer has been recognized with numerous honors and prestigious appointments that highlight her global leadership in One Health and public health. She has served as a United Nations Environment Programme (UNEP) One Health Expert and Technical Advisory Group member for the Nature for Health initiative, representing Latin America and later co-chairing its expert committee. Her expertise has been sought by the World Health Organization’s Global Preparedness Monitoring Board, PREZODE’s International Data Working Group, and the Agence Nationale de la Recherche in France for evaluating pandemic prevention strategies. She has also been appointed as a Fulbright Program Adviser, National Scholar Program Ambassador, and Reviewer, reflecting her commitment to international education and research exchange. In addition, her editorial leadership roles as Senior Editor of CABI One Health and Editor-in-Chief of Beyond One Ocean Health stand as significant honors that demonstrate her influence in shaping global scientific dialogue. These achievements collectively underscore her distinguished reputation as a trusted advisor, scholar, and thought leader in global health.

Publications Top Noted

Effects of Covid-19 Pandemic in the Surveillance and Control of Neglected Tropical Diseases and Malaria: A Systematic Review

Year: 2025

Protecting Urban Wildlife Fauna, Fighting Zoonoses, and Preventing Biophobia in Brazil

Year: 2025

Conclusion

Dr. Christina Pettan-Brewer is a highly suitable candidate for the Best Researcher Award. Her career exemplifies global leadership, interdisciplinary research, and a strong commitment to advancing One Health, pandemic prevention, and planetary health. With a proven record of academic excellence, international collaboration, and impactful advisory roles, she stands out as a researcher whose work bridges science, policy, and education. Addressing minor improvements related to visibility of individual research outputs would further strengthen her profile, but her broad and meaningful contributions make her a compelling and deserving nominee for this recognition.

 

WEN CHANG TSENG | Medicine and Health Sciences | Best Researcher Award

Published on by Research Hypothesis

WEN CHANG TSENG | Medicine and Health Sciences | Best Researcher Award

Mr WEN CHANG TSENG, Cathay General Hospital/Departmentof Radiology, Taiwan

Mr. Wen Chang Tseng is an accomplished medical radiologic technologist and deputy director with extensive expertise in diagnostic radiology and clinical trials. 📡🔬 With a career spanning over two decades (since 1999), he has contributed significantly to medical imaging and radiology, playing a key role in multinational clinical trials on ankylosing spondylitis and rheumatoid arthritis. 🏥 His work in advancing radiological technology has made a substantial impact in medical research, ensuring high standards in diagnostic procedures. 🎯 His dedication to improving patient care through innovative imaging techniques and clinical studies has earned him recognition as a leading expert in his field. 🌍 His contributions to Phase II and Phase III multinational studies highlight his commitment to advancing diagnostic radiology. 📈 His leadership in technology development, combined with his research experience, makes him a deserving recipient of the Best Researcher Award. 🏅👏

Publication Profile

Scopus

Education

Mr. Wen Chang Tseng holds a strong educational background in medical imaging and engineering. 🏛️ He earned his degree from the Department of Medical Imaging and Radiological Technology at Yuanpei University, where he gained in-depth knowledge of radiological sciences and medical imaging techniques. 🏥🔍 Expanding his technical expertise, he further pursued studies in the Department of Electrical Engineering at Chung Yuan Christian University, enhancing his understanding of technological applications in medical diagnostics. ⚡🖥️ His combined knowledge of radiology and electrical engineering allows him to develop and implement cutting-edge imaging solutions for enhanced patient diagnosis and treatment. 🏆 His education has provided a robust foundation for his career in medical radiology, clinical trials, and diagnostic imaging research. 🎯 His multidisciplinary academic training continues to support his innovative contributions to medical technology and radiology advancements. 📡🩻

Experience

With over two decades of experience in the field of diagnostic radiology, Mr. Wen Chang Tseng has been a cornerstone of medical imaging and radiologic technology. 🏆 Since 1999, he has been actively involved in the Diagnostic Radiology Department, applying his expertise in radiological imaging to enhance diagnostic accuracy. 🏥 His dedication and leadership have led him to serve as a Medical Radiologic Technologist and Deputy Director of Technology, where he has played a pivotal role in managing radiological procedures, research coordination, and advanced imaging technologies. 🔬🖥️ His work extends to supervising and conducting multinational clinical trials focusing on ankylosing spondylitis and rheumatoid arthritis. 🌎📊 His contributions have improved clinical imaging protocols and enhanced the reliability of diagnostic techniques. 🎯 His leadership in medical imaging research and development has made a lasting impact on the field of radiology. 🏅👏

Awards & Honors

Mr. Wen Chang Tseng’s contributions to medical imaging and radiological technology have been widely recognized through numerous accolades. 🏆 His expertise in diagnostic radiology and clinical trial research has earned him prestigious honors, including commendations for excellence in radiologic innovation and clinical research advancements. 🌟 As a leader in medical imaging research, he has been an integral part of groundbreaking Phase II and Phase III multinational studies on ankylosing spondylitis and rheumatoid arthritis. 📈 His pioneering role in clinical trials has led to significant improvements in diagnostic imaging standards, contributing to global advancements in radiology. 🌍 He has also been acknowledged by international research institutions for his commitment to technological advancements in radiologic sciences. 🔬 His dedication and innovation make him a distinguished figure in the field, making him a deserving recipient of the Best Researcher Award. 🏅🎯

Research Focus

Mr. Wen Chang Tseng specializes in diagnostic radiology, medical imaging technology, and clinical trial research. 📡 His work focuses on enhancing imaging techniques for ankylosing spondylitis and rheumatoid arthritis through Phase II and Phase III multinational clinical trials. 🏥 He has played a crucial role in advancing radiologic assessment methods, ensuring precise imaging for improved diagnosis and treatment planning. 🎯 His research integrates medical imaging with electrical engineering, allowing for the development of cutting-edge radiologic technologies. 🖥️⚡ His contributions to clinical trials have led to refined imaging protocols, benefiting global healthcare standards. 🌍 His multidisciplinary expertise in radiology and technology has driven innovation in diagnostic procedures, improving efficiency and accuracy in detecting musculoskeletal disorders. 📊 His research continues to shape the future of medical imaging, contributing to better patient care and medical advancements. 🏆

Publication Top Notes

Assessing the seasonality of occupancy number-associated CO2 level in a Taiwan hospital